INBX
HOLD / NEUTRALMeanRevComposite
42.00
Technical
89.40
Fundamental
26.30
Rank
—
Price
114.34
Hurst
0.03
As of
Sep 9, 2026
Daily
Inhibrx Biosciences, Inc.
HealthcareBiotechnologyInhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic drugs to treat serious illnesses. The company's pipeline includes INBRX-109, a tetravalent candidate in early testing that targets death-receptor 5 for chondrosarcoma, and INBRX-106, a hexavalent antibody-based candidate targeting OX40 for various metastatic cancers including lung cancer, melanoma, gastric cancer, and renal cell carcinoma. The company was established in 2024 and is located in La Jolla, California.
Market cap
$1.5B
P/E (trailing)
—
P/E (forward)
-11.96
PEG ratio
—
Dividend yield
—
Beta
3.67
52w range
26.20 – 155.29
Return on equity
-1773.60%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 104.73 (+293.0%) · range 26.65–141.84
Cycle position
55/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 8 · NOT READY · exit proximity 0
Conviction
21/ 100 · maturity 14%
VScore.0915
Buildup.3034
EMA entry setup.388
Fundamentals.2326
Volume profile
POC
93.56
Price vs POC
+11.9%
Overhead supply
45%
Runway
open sky
Value area 80.82–123.93 · 45% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 1.000 | Sep 9, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -3.18% | -1.28% | 2/20d |
| 40d | -3.18% | -1.28% | 2/40d |